$DGX

DGX SWOT Analysis: Key Insights from the 10-Q Filing

Quest Diagnostics (DGX) released its Q3 2026 report, showing strong revenue from clinical testing but facing valuation concerns. The company has a GF Score of 76/100, with strengths in market presence and innovation, but weaknesses in financial stability and legal challenges. Opportunities include growing demand for diagnostic services and healthcare IT solutions, while threats include competition and regulatory risks. The stock is currently overvalued by about 20% according to GF Value.

Original reporting
Published Oct 24, 2026, 4:02 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 24, 2026, 8:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$DGX
Bearish
high confidence
Mentioned
$DGX
Relevance
4/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$DGXBearishLow
01

Why it matters

The analysis suggests valuation concerns and legal reserves may pressure the stock, while growth initiatives could offset risks.

02

Market read

The filing provides fresh financial data that may influence investor sentiment on DGX and comparable diagnostic firms.

03

What to watch

Potential upside from upcoming AI‑driven automation initiatives and expanding risk‑assessment services for insurers.

Relevance 4/10Novelty 4/10Timing: post‑10‑Q release

Background

Quest Diagnostics released its quarterly 10‑Q filing, prompting a SWOT analysis that evaluates financial health, legal exposure, and growth opportunities.

Company-level read

Ticker impact

$DGXBearishHigh confidence
Context

The article reports Quest Diagnostics' 10‑Q filing with new financial metrics, legal reserve figures and valuation assessment.

Expected impact

potential downside pressure as valuation concerns and legal reserves weigh on the stock

Evidence & confidence

The SWOT highlights overvaluation (~20% above GF value) and $32 M legal reserves, which could prompt investors to reassess the price.

Market effects

Diagnostic testing sector may see heightened scrutiny on valuation multiples as DGX's overvaluation is highlighted.

U.S. healthcare services market could experience modest re‑rating pressure.

Limited; the analysis is specific to Quest Diagnostics and does not affect broader global markets.

Counterpoint

Despite the overvaluation flag, DGX's strong cash flow and market dominance could support the current price.

Key entities

  • Quest Diagnostics Inc.

    U.S. provider of diagnostic testing and information services (ticker DGX).

Related articles

$DGXMed

New York State Data Exposed Following Quest Diagnostic Breach

Quest Diagnostics disclosed a data breach in its Quanum Lab Services Manager system, exposing patient records, including names, Social Security numbers, and medical information. The breach was contained, but the exact number of affected individuals is still under investigation. Quest will notify impacted patients and offer identity theft monitoring services. The company serves 1 in 3 American adults annually.

$DGXMed

Quest Diagnostics says unauthorized access to lab-ordering system exposed patient records

Quest Diagnostics reported unauthorized access to its Quanum Lab Services Manager system, exposing patient records. The breach was discovered on Oct. 21, 2026, and disclosed the next day. The company is investigating with outside experts and has notified law enforcement. No disruption to customer operations was reported, and no threat group has claimed responsibility. Quest has temporarily paused access to affected systems and recommended alternative methods for orders and results.

$DGXLow

Medical Testing Giant Quest Diagnostics Confirms Massive Security Breach Exposing Sensitive Patient Records Amid a Coordinated Global Hacking Surge

Quest Diagnostics confirmed a security breach exposing patient records via its Quanum Lab Services Manager system. The breach, discovered on October 21, impacted protected health information and personal data. The company has taken steps to contain the breach, but the full extent of the damage is still under investigation. This incident is part of a broader surge in global cyberattacks, including a critical flaw in the PHP programming language.

$DGXMedAI 8/10

Quest Diagnostics Q3 2026 Revenue Rises to $3.1B, Diluted EPS Up to $2.78

Quest Diagnostics reported Q3 2026 revenue of $3.1B, up 10% YoY, with diluted EPS rising to $2.78. Operating income increased to $479M. Year-to-date revenue reached $9.035B, with net income attributable to Quest at $884M. The company maintained strong cash flow and returned capital through buybacks and dividends, but noted rising operating costs and debt.